Sobi's Strategic Share Repurchase Initiative
The Board of Directors of Swedish Orphan Biovitrum AB, commonly known as Sobi, has authorized a significant decision to repurchase shares. This initiative is aimed at fulfilling the company's commitments associated with its long-term incentive programs. By enhancing its financial strategies, Sobi demonstrates a commitment to maximizing shareholder value while positioning itself for growth.
Details of the Share Repurchase Resolution
During a recent Annual General Meeting, the company approved the issuance of approximately 1,412,788 redeemable and convertible class C shares. This resolution enables Sobi to manage its long-term incentive commitments effectively. The Board of Directors is now empowered to repurchase these shares at a price not less than 100% and not more than 105% of their quotient value, thus offering a secure investment approach for current shareholders.
Executing the Repurchase: Key Timeline
Moving forward, the Board has initiated the execution of its repurchase authorization, contingent upon subscription and payment by Svenska Handelsbanken AB. The current plan includes acquiring all issued class C shares at a price equivalent to their quotient value of about SEK 0.55 per share. This repurchase is set to take place from July 16 through November 7, providing a clear timeframe for stakeholders to monitor the execution of this strategic decision.
Impact of the Share Repurchase on Sobi's Financial Position
As of now, Sobi holds 11,377,680 common shares and no class C shares. Following the completion of this planned repurchase, all acquired class C shares are expected to be converted into common shares, bringing the total number of Sobi’s common shares to approximately 12,790,468. This conversion is crucial for enhancing the liquidity and overall financial robustness of the company moving forward.
About Sobi
Sobi is a specialized biopharmaceutical company dedicated to discovering and delivering breakthrough therapies that significantly impact the lives of individuals affected by rare diseases. With a dedicated workforce of around 1,900 employees spread across various regions including Europe, North America, the Middle East, Asia, and Australia, Sobi is committed to innovation that transforms everyday lives. In its latest financial year, the company reported an impressive revenue of SEK 26 billion. Notably, Sobi's shares are traded on Nasdaq Stockholm under the ticker symbol STO:SOBI.
Contact and Further Information
For any inquiries or further details on Sobi’s initiatives and financial strategies, the Investor Relations Team is available for engagement. For press inquiries, please reach out to the Sobi Media contacts directly. Investment and financial information can make a significant difference, and Sobi remains committed to transparency and support for its shareholders.
Frequently Asked Questions
1. What prompted Sobi to authorize a share repurchase?
The share repurchase was authorized to fulfill commitments under long-term incentive programs while simultaneously enhancing shareholder value.
2. When is the period for the planned share repurchase?
The share repurchase is scheduled to take place from July 16 to November 7.
3. How many class C shares will Sobi repurchase?
Sobi plans to repurchase all 1,412,788 issued class C shares.
4. What is the price range for the share repurchase?
Shares will be repurchased at a price not less than 100% and not more than 105% of their quotient value.
5. What are the anticipated benefits of converting class C shares to common shares?
By converting class C shares to common shares, Sobi aims to increase liquidity and strengthen its financial position.
